Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 26 clinical trials
featured
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients with Hematologic Malignancies and Other Indications

Background: Cord blood transplants can treat cancers and other diseases in children and adults. The U.S. Food and Drug Administration (FDA) requires cord blood to be collected and stored under certain safety standards. However, most available cord blood units were collected before the FDA set these standards. These units may …

myelodysplastic syndromes
aplastic anemia
anemia studies
anemia
myelodysplastic syndrome (mds)
  • 51 views
  • 22 Dec, 2020
  • 1 location
Pilot Study of Reduced-Intensity Hematopoietic Stem Cell Transplant of DOCK8 Deficiency

Background -DOCK8 deficiency is a genetic disorder that affects the immune system and can lead to severe recurrent infections and possible death from infections or certain types of cancers, including blood cancers. A stem cell transplant is a life-saving treatment for this condition. In this study we are evaluating the …

  • 1 views
  • 26 Sep, 2021
  • 1 location
Post Transplant High-Dose Cy as GvHD Prophylaxis in 1 HLA Mismatched Unrelated HSCT for Myeloid Malignancies

The experimental treatment consists in the application of a therapeutic strategy with post Transplant High-Dose Cyclophosphamide as GvHD Prophylaxis in Patients Receiving 1-Antigen/Allele HLA Mismatched (7/8 matched) Unrelated Hemopoietic Stem Cell Transplantation for Myeloid Malignancies.

  • 0 views
  • 27 Aug, 2021
  • 33 locations
T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Conditioned With a Reduced Intensity Regimen in Patients With Hematologic Malignancies and Aplastic Anemia

The main purpose of this study is to learn if a new combination of chemotherapy, in combination with low-dose radiation, will be safe for the patient, and at the same time provide the best opportunity to cure the bone marrow cancer. The combination of chemotherapy and radiation described in the …

  • 13 views
  • 09 Jun, 2021
  • 2 locations
Iobenguane I-131 or Crizotinib and Standard Therapy in Treating Younger Patients With Newly-Diagnosed High-Risk Neuroblastoma or Ganglioneuroblastoma

This phase III trial studies iobenguane I-131 or crizotinib and standard therapy in treating younger patients with newly-diagnosed high-risk neuroblastoma or ganglioneuroblastoma. Radioactive drugs, such as iobenguane I-131, may carry radiation directly to tumor cells and not harm normal cells. Crizotinib may stop the growth of tumor cells by blocking …

isotretinoin
busulfan
high-risk neuroblastoma
stem cell transplantation
ganglioneuroblastoma
  • 66 views
  • 03 Sep, 2021
  • 105 locations
Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases

The hypothesis for this study is that a preparative regimen that maximizes host immunosuppression without myeloablation will be well tolerated and sufficient for engraftment of donor hematopoietic cells. It is also to determine major toxicities from these conditioning regimens, within the first 100 days after transplantation.

methotrexate
fludarabine
hydroxyurea
hemoglobin s
graft versus host disease
  • 142 views
  • 25 Jan, 2021
  • 20 locations
BMT-06: Study of Intensity Modulated Total Marrow Irradiation (IM-TMI)

Pre-transplant conditioning will include targeted total marrow irradiation (TMI) at a dose of 6Gy. Graft-versus-host disease prophylaxis will include cyclophosphamide 50 mg/kg on Day +3 and 4

remission
cytopenia
chromosome abnormality
leukemia
myelodysplastic syndromes
  • 18 views
  • 04 Jun, 2021
  • 1 location
Tocilizumab for the Prevention of Graft Failure and GVHD in Haplo-Cord Transplantation

The purpose of this study is to evaluate the safety of reducing and ultimately eliminating anti-thymocyte globulin (ATG) from the haplo-cord transplant conditioning regimen and replacing it with

remission
leukemia
chronic myeloid leukemia
myelodysplastic syndromes
transplant conditioning
  • 0 views
  • 26 Jan, 2021
  • 1 location
TEAM (Thiotepa Etoposide Cytosar Melphalan ) for AutoSCT in Lymphoma

, -2 and melphalan 140 mg/m2 on day -1, pre transplantation conditioning regimen may allow transplantation with lower transplant related toxicity and thus improve outcome in this setting. Toward this

thiotepa
melphalan
hodgkin's disease
etoposide
cell transplantation
  • 0 views
  • 25 Jan, 2021
  • 1 location
TT52CAR19 Therapy for B-cell Acute Lymphoblastic Leukaemia (B-ALL)

are to be used in a time-limited manner for their anti-leukaemia effects and then depleted by standard pre- transplant conditioning.

  • 0 views
  • 27 Jan, 2021
  • 1 location